The IMPACT-HF trial is testing a treatment strategy focused on improving the use of β-blockers in the heart failure population. This trial is expected to yield important information about the safety and tolerability of β-blockers, as well as about titration patterns of dosing and response to therapy in patients admitted with heart failure. The results of the IMPACT-HF trial were presented at a satellite symposium at the 2002 American Heart Association Annual Scientific Session.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine